Prestige Consumer Healthcare (PBH) Projected to Release Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is expected to announce its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $0.89 per share and revenue of $249.6810 million for the quarter. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Individuals may visit the the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The business had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. During the same quarter in the prior year, the firm earned $1.32 EPS. Prestige Consumer Healthcare’s revenue for the quarter was down 5.0% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $52.17 on Thursday. The firm has a market cap of $2.47 billion, a PE ratio of 13.34, a price-to-earnings-growth ratio of 1.66 and a beta of 0.35. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $75.63. The business’s fifty day simple moving average is $48.22 and its 200-day simple moving average is $56.62.

Analysts Set New Price Targets

Several brokerages recently issued reports on PBH. Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Finally, Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $70.75.

Insider Buying and Selling

In other news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the transaction, the vice president directly owned 42,820 shares in the company, valued at $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently modified their holdings of PBH. State Street Corp lifted its stake in Prestige Consumer Healthcare by 1.4% during the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock worth $122,917,000 after acquiring an additional 27,721 shares in the last quarter. Morgan Stanley increased its stake in Prestige Consumer Healthcare by 6.3% during the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock worth $74,209,000 after purchasing an additional 71,078 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Prestige Consumer Healthcare by 5.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock worth $45,568,000 after purchasing an additional 35,126 shares during the period. Bank of America Corp DE lifted its position in shares of Prestige Consumer Healthcare by 19.1% during the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after purchasing an additional 115,459 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in shares of Prestige Consumer Healthcare by 15.7% during the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock worth $39,807,000 after purchasing an additional 86,373 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).